Article

TUNA patients show no more need for retreatment after 5 years

When drugs have failed, transurethral needle ablation (TUNA) has shown to be an effective long-term option for men suffering from BPH, according to recently published data.

Related Videos
3d rendered illustration - bladder | Image Credit: © Sebastian Kaulitzki - stock.adobe.com
Wayne Kuang, MD, answers a question during a Zoom video interview
1 expert is featured in this series.
Raveen Syan, MD, FPMRS, answers a question during a Zoom video interview
Mohamad Baker Berjaoui, MD, answers a question during a Zoom video interview
Related Content
Navigating work-life balance: VUMC’s Family Planning for Surgeons Series
December 23rd 2024

Navigating work-life balance: VUMC’s Family Planning for Surgeons Series

Lauren E. Corona, MD
"I hope that [attendees] will be exposed to a community where they feel that they're able to freely ask questions, gain accurate information, and feel heard, validated, and connected," says Lauren E. Corona, MD.
Episode 1 Podcast: Understanding Overactive Bladder (OAB): Pathophysiology, Diagnosis, and Management in Older Adults
November 27th 2024

Episode 1 Podcast: Understanding Overactive Bladder (OAB): Pathophysiology, Diagnosis, and Management in Older Adults

Wayne Kuang, MD Bilal Chughtai, MD
Experts discuss overactive bladder and the impacts on quality of life, distinguishing OAB from BPH, and how a delayed diagnosis can worsen symptoms.
PSMA-PET shows diagnostic accuracy in initial staging of prostate cancer
December 20th 2024

PSMA-PET shows diagnostic accuracy in initial staging of prostate cancer

Hannah Clarke
The investigators found a positive correlation between PSA levels and SUVmax.
Former MLB player Dave Winfield shares lessons from baseball, philanthropy
November 15th 2024

Former MLB player Dave Winfield shares lessons from baseball, philanthropy

Urology Times staff
In this episode of Speaking of Urology, former MLB player Dave Winfield shares lessons he’s learned throughout his professional baseball career and his work in philanthropy.
First patient dosed in phase 1 trial of ADI-270 in ccRCC
December 19th 2024

First patient dosed in phase 1 trial of ADI-270 in ccRCC

Hannah Clarke
Initial data from the trial are expected to be released in the first half of 2025.
FDA greenlights phase 1/2 trial of gene editing therapy for primary hyperoxaluria 1
December 19th 2024

FDA greenlights phase 1/2 trial of gene editing therapy for primary hyperoxaluria 1

Hannah Clarke
The redePHine trial is expected to launch in the first half of 2025.
© 2024 MJH Life Sciences

All rights reserved.